Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer

Journal of Clinical Investigation

Volumn 121, Issue 7, 2011, Pages 2709-2722

  Pabla, Navjotsingh ^a   Dong, Guie ^a   Jiang, Man ^a   Huang, Shuang ^a   Kumar, M Vijay ^b   Messing, Robert O ^c   Dong, Zheng ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA SAN FRANCISCO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C DELTA; PROTEIN P53; PROTEIN TYROSINE KINASE; ROTTLERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER MODEL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; KIDNEY CELL; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TUBULE CELL; MOUSE; NEPHROTOXICITY; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; RENAL PROTECTION; TUMOR XENOGRAFT;

ACETOPHENONES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOPYRANS; CELL LINE, TUMOR; CISPLATIN; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; KIDNEY; KIDNEY TUBULES, PROXIMAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM TRANSPLANTATION; NEOPLASMS; PROTEIN KINASE C-DELTA; SRC-FAMILY KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79959934717     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI45586     Document Type: Article

References (69)

1. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265-7279. (Pubitemid 37487159)
2. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307-320. (Pubitemid 41130944)
3. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Perez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem. 2007;7(1):3-18. (Pubitemid 46062402)
4. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci U S A. 2002;99(7):4592-4595. (Pubitemid 34286029)
5. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol. 2008;61(6):903-909.
6. Miller RP, Tadagavadi RK, Ramesh G, Reeves PG. Mechanisms of cisplatin nephrotoxicity. Toxins. 2010;2(11):2490-2518.
7. Pabla N, Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994-1007. (Pubitemid 351543900)
8. Price PM, Megyesi J, Safirstein RL. Cell cycle regulation: repair and regeneration in acute renal failure. Semin Nephrol. 2003;23(5):449-459. (Pubitemid 37176690)
9. Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates Cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol. 2001;12(12):2683-2690. (Pubitemid 33115415)
10. Agarwal A, Balla J, Alam J, Croatt AJ, Nath KA. Induction of heme oxygenase in toxic renal injury: a protective role in cisplatin nephrotoxicity in the rat. Kidney Int. 1995;48(4):1298-1307.
11. Arany I, Megyesi JK, Kaneto H, Price PM, Safirstein RL. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol. 2004;287(3):F543-F549. (Pubitemid 39095970)
12. Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int. 1998;53(2):394-401. (Pubitemid 28097855)
13. Kuwana H, et al. The phosphoinositide-3 kinase gamma-Akt pathway mediates renal tubular injury in cisplatin nephrotoxicity. Kidney Int. 2008; 73(4):430-445. (Pubitemid 351186288)
14. Liu H, Baliga R. Endoplasmic reticulum stress-associated caspase 12 mediates cisplatin-induced LLC-PK1 cell apoptosis. J Am Soc Nephrol. 2005;16(7):1985-1992. (Pubitemid 41716429)
15. Megyesi J, Safirstein RL, Price PM. Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest. 1998;101(4):777-782. (Pubitemid 28096074)
16. Nowak G. Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells. J Biol Chem. 2002;277(45):43377-43388. (Pubitemid 35285726)
17. Park MS, De Leon M, Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol. 2002;13(4):858-865. (Pubitemid 34274081)
18. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002;110(6):835-842.
19. Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol. 2005;289(1):F166-F174. (Pubitemid 40863584)
20. Shiraishi F, et al. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am J Physiol Renal Physiol. 2000;278(5):F726-F736. (Pubitemid 30351074)
21. Tsuruya K, et al. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int. 2003;63(1):72-82. (Pubitemid 35463908)
22. Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol. 2008;19(5):923-932.
23. Yu F, Megyesi J, Safirstein RL, Price PM. Involvement of the CDK2-E2F1 pathway in cisplatin cytotoxicity in vitro and in vivo. Am J Physiol Renal Physiol. 2007;293(1):F52-F59. (Pubitemid 47345002)
24. Goligorsky MS. How to keep kidneys safe while shrinking tumors: the conundrum of cisplatin action. Am J Physiol Renal Physiol. 2007;293(1):F50-F51. (Pubitemid 47345001)
25. Gutcher I, Webb PR, Anderson NG. The isoform-specific regulation of apoptosis by protein kinase C. Cell Mol Life Sci. 2003;60(6):1061-1070. (Pubitemid 36791911)
26. Jackson DN, Foster DA. The enigmatic protein kinase Cdelta: complex roles in cell proliferation and survival. Faseb J. 2004;18(6):627-636. (Pubitemid 38451785)
27. Steinberg SF. Distinctive activation mechanisms and functions for protein kinase Cdelta. Biochem J. 2004;384(pt 3):449-459. (Pubitemid 40018958)
28. Steinberg SF. Structural basis of protein kinase C isoform function. Physiol Rev. 2008;88(4):1341-1378.
29. Basu A. Involvement of protein kinase C-delta in DNA damage-induced apoptosis. J Cell Mol Med. 2003;7(4):341-350. (Pubitemid 44151685)
30. Brodie C, Blumberg PM. Regulation of cell apoptosis by protein kinase c delta. Apoptosis. 2003;8(1):19-27. (Pubitemid 36133134)
31. Reyland ME. Protein kinase Cdelta and apoptosis. Biochem Soc Trans. 2007;35(pt 5):1001-1004.
32. Faubel S, Ljubanovic D, Reznikov L, Somerset H, Dinarello CA, Edelstein CL. Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int. 2004;66(6):2202-2213. (Pubitemid 41115283)
33. Wei Q, Dong G, Franklin J, Dong Z. The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int. 2007;72(1):53-62. (Pubitemid 47014446)
34. Wei Q, Dong G, Yang T, Megyesi J, Price PM, Dong Z. Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol. 2007;293(4):F1282-F1291. (Pubitemid 47583963)
35. Brooks C, Wei Q, Cho S, Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest. 2009;119(5):1275-1285.
36. Ghayur T, et al. Proteolytic activation of protein kinase C delta by an ICE/CED 3-like protease induces characteristics of apoptosis. J Exp Med. 1996;184(6):2399-2404. (Pubitemid 27023739)
37. DeVries-Seimon TA, Ohm AM, Humphries MJ, Reyland ME. Induction of apoptosis is driven by nuclear retention of protein kinase C delta. J Biol Chem. 2007;282(31):22307-22314. (Pubitemid 47267361)
38. Soltoff SP. Rottlerin: an inappropriate and ineffective inhibitor of PKCdelta. Trends Pharmacol Sci. 2007;28(9):453-458. (Pubitemid 47371266)
39. Chou WH, et al. Neutrophil protein kinase Cdelta as a mediator of stroke-reperfusion injury. J Clin Invest. 2004;114(1):49-56.
40. Cummings BS, Schnellmann RG. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther. 2002;302(1):8-17. (Pubitemid 34680415)
41. Jiang M, et al. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene. 2006;25(29):4056-4066. (Pubitemid 44024868)
42. Jiang M, Yi X, Hsu S, Wang CY, Dong Z. Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity. Am J Physiol Renal Physiol. 2004;287(6):F1140-F1147. (Pubitemid 39507222)
43. Seth R, Yang C, Kaushal V, Shah SV, Kaushal GP. p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. J Biol Chem. 2005;280(35):31230-31239. (Pubitemid 41291860)
44. Pabla N, Huang S, Mi QS, Daniel R, Dong Z. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem. 2008;283(10):6572-6583.
45. Jiang M, Dong Z. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J Pharmacol Exp Ther. 2008;327(2):300-307.
46. Molitoris BA, et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol. 2009;20(8):1754-1764.
47. Tsuruya K, et al. Involvement of p53-transactivated Puma in cisplatin-induced renal tubular cell death. Life Sciences. 2008;83(15-16):550- 556.
48. Sheikh-Hamad D, et al. Cellular and molecular studies on cisplatin-induced apoptotic cell death in rat kidney. Arch Toxicol. 2004;78(3):147-155. (Pubitemid 38657196)
49. Jo SK, Cho WY, Sung SA, Kim HK, Won NH. MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int. 2005;67(2):458-466. (Pubitemid 40139837)
50. Liu M, et al. A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J Am Soc Nephrol. 2006;17(3):765-774.
51. Tadagavadi RK, Reeves WB. Renal dendritic cells ameliorate nephrotoxic acute kidney injury. J Am Soc Nephrol. 2010;21(1):53-63.
52. Zhang L, et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol. 2002;161(6):2295-2309. (Pubitemid 35434873)
53. Chen L, et al. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci U S A. 2001;98(20):11114-11119. (Pubitemid 32928691)
54. Qi X, Inagaki K, Sobel RA, Mochly-Rosen D. Sustained pharmacological inhibition of deltaPKC protects against hypertensive encephalopathy through prevention of blood-brain barrier breakdown in rats. J Clin Invest. 2008;118(1):173-182.
55. Bright R, et al. Protein kinase C delta mediates cerebral reperfusion injury in vivo. J Neurosci. 2004;24(31):6880-6888. (Pubitemid 39045444)
56. Yoshida K, Liu H, Miki Y. Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage. J Biol Chem. 2006;281(9):5734-5740. (Pubitemid 43847672)
57. Ryer EJ, et al. Protein kinase C delta induces apoptosis of vascular smooth muscle cells through induction of the tumor suppressor p53 by both p38-dependent and p38-independent mechanisms. J Biol Chem. 2005;280(42):35310- 35317. (Pubitemid 41532719)
58. McCracken MA, Miraglia LJ, McKay RA, Strobl JS. Protein kinase C delta is a prosurvival factor in human breast tumor cell lines. Mol Cancer Ther. 2003;2(3):273-281.
59. Wang Q, Wang X, Evers BM. Induction of cIAP-2 in human colon cancer cells through PKC delta/NF-kappa B. J Biol Chem. 2003;278(51):51091-51099. (Pubitemid 38020344)
60. Clark AS, West KA, Blumberg PM, Dennis PA. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res. 2003;63(4):780-786. (Pubitemid 36231976)
61. Ringshausen I, Oelsner M, Weick K, Bogner C, Peschel C, Decker T. Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL. Leukemia. 2006;20(3):514-520. (Pubitemid 43291752)
62. Brenner W, et al. Migration of renal carcinoma cells is dependent on protein kinase Cdelta via beta1 integrin and focal adhesion kinase. Int J Oncol. 2008;32(5):1125-1131.
63. De Servi B, Hermani A, Medunjanin S, Mayer D. Impact of PKCdelta on estrogen receptor localization and activity in breast cancer cells. Oncogene. 2005;24(31):4946-4955. (Pubitemid 41129098)
64. Grossoni VC, Falbo KB, Kazanietz MG, de Kier Joffe ED, Urtreger AJ. Protein kinase C delta enhances proliferation and survival of murine mammary cells. Mol Carcinog. 2007;46(5):381-390. (Pubitemid 46744458)
65. Kiley SC, Clark KJ, Goodnough M, Welch DR, Jaken S. Protein kinase C delta involvement in mammary tumor cell metastasis. Cancer Res. 1999;59(13):3230-3238. (Pubitemid 29316027)
66. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136(5):823-837.
67. Yamamoto T, Matsuzaki H, Kamada S, Ono Y, Kikkawa U. Biochemical assays for multiple activation states of protein kinase C. Nat Protoc. 2006;1(6):2791-2795.
68. Brooks C, et al. Bak regulates mitochondrial morphology and pathology during apoptosis by interacting with mitofusins. Proc Natl Acad Sci U S A. 2007;104(28):11649-11654. (Pubitemid 47175067)
69. Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2009;296(3):F505-F511.